References
- Stadel B V. Oral contraceptives and cardiovascular disease (first of two parts. New Engl J Med 1981; 305: 612–18
- Mammen E F. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 1982; 142: 781–90
- Stolley P D., Tonascia J A., Tockman M S., Sartwell P E., Rutledge A H., Jacobs M P. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975; 102: 197–208
- Meade T W., Greenberg G, Thompson S G. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 30-microgram oestrogen preparations. Br Med J 1980; 280: 1157–61
- Stadel B V. Oral contraceptives and cardiovascular disease (second of two parts). New Engl J Med 1981; 305: 672–7
- Cartwright A. How many children?. Routledge & Kegan Paul, London 1976
- Barrett J C., Marshall J. The risk of conception on different days of the menstrual cycle. Population Studies 1969; 23: 455–61
- Beard R J. Risks and problems for the older parent: changing patterns of conception and fertility. Proceedings of the sixteenth annual symposium of the Eugenics Society. 1979. Academic Press, London
- Guillebaud J. Contraception for the older woman. Obstet Gynecol (Suppl 2) 1985; 5: 570–7
- Baillie P. Oestrogenic effects of the triphasic oral contraceptive agents. S Afr Med J 1985; 68: 706
- Cullberg G, Dovre P A., Lindstedt G, Steffensen K. On the use of plasma proteins as indicators of the metabolic effects of oral contraceptives. Acta Obstet Gynecol Scand (Suppl) 1982; 111: 47–54
- Cullberg G. Pharmacodynamic studies on desogestrel administered alone and in comparison with ethinylestradiol. Acta Obstet Gynecol Scand (Suppl) 1985; 133
- Samsioe G. Study on effect of 30 μg ethinylestradiol (EE)-t-150 μg desogestrel on lipid and lipoprotein metabolism in healthy volunteers, also in comparison with 30 μg EE+150 μg levonorgestrel. Acta Obstet Gynecol Scand (Suppl) 1982; 111: 55–60